<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34747982</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6114</ISSN><JournalIssue CitedMedium="Internet"><Volume>182</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA internal medicine</Title><ISOAbbreviation>JAMA Intern Med</ISOAbbreviation></Journal><ArticleTitle>Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic.</ArticleTitle><Pagination><StartPage>19</StartPage><EndPage>25</EndPage><MedlinePgn>19-25</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamainternmed.2021.6454</ELocationID><Abstract><AbstractText Label="IMPORTANCE">After an infection by SARS-CoV-2, many patients present with persistent physical symptoms that may impair their quality of life. Beliefs regarding the causes of these symptoms may influence their perception and promote maladaptive health behaviors.</AbstractText><AbstractText Label="OBJECTIVE">To examine the associations of self-reported COVID-19 infection and SARS-CoV-2 serology test results with persistent physical symptoms (eg, fatigue, breathlessness, or impaired attention) in the general population during the COVID-19 pandemic.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">Participants in this cross-sectional analysis were 26&#x202f;823 individuals from the French population-based CONSTANCES cohort, included between 2012 and 2019, who took part in the nested SAPRIS and SAPRIS-SERO surveys. Between May and November 2020, an enzyme-linked immunosorbent assay was used to detect anti-SARS-CoV-2 antibodies. Between December 2020 and January 2021, the participants reported whether they believed they had experienced COVID-19 infection and had physical symptoms during the previous 4 weeks that had persisted for at least 8 weeks. Participants who reported having an initial COVID-19 infection only after completing the serology test were excluded.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Logistic regressions for each persistent symptom as the outcome were computed in models including both self-reported COVID-19 infection and serology test results and adjusting for age, sex, income, and educational level.</AbstractText><AbstractText Label="RESULTS">Of 35&#x202f;852 volunteers invited to participate in the study, 26&#x202f;823 (74.8%) with complete data were included in the present study (mean [SD] age, 49.4 [12.9] years; 13&#x202f;731 women [51.2%]). Self-reported infection was positively associated with persistent physical symptoms, with odds ratios ranging from 1.39 (95% CI, 1.03-1.86) to 16.37 (95% CI, 10.21-26.24) except for hearing impairment (odds ratio, 1.45; 95% CI, 0.82-2.55) and sleep problems (odds ratio, 1.14; 95% CI, 0.89-1.46). A serology test result positive for SARS-COV-2 was positively associated only with persistent anosmia (odds ratio, 2.72; 95% CI, 1.66-4.46), even when restricting the analyses to participants who attributed their symptoms to COVID-19 infection. Further adjusting for self-rated health or depressive symptoms yielded similar results. There was no significant interaction between belief and serology test results.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">The findings of this cross-sectional analysis of a large, population-based French cohort suggest that persistent physical symptoms after COVID-19 infection may be associated more with the belief in having been infected with SARS-CoV-2 than with having laboratory-confirmed COVID-19 infection. Further research in this area should consider underlying mechanisms that may not be specific to the SARS-CoV-2 virus. A medical evaluation of these patients may be needed to prevent symptoms due to another disease being erroneously attributed to "long COVID."</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Matta</LastName><ForeName>Joane</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Paris, "Population-based Cohorts Unit," Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale (INSERM), Paris Saclay University, Universit&#xe9; de Versailles-Saint-Quentin-en-Yvelines, UMS 011, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiernik</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Paris, "Population-based Cohorts Unit," Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale (INSERM), Paris Saclay University, Universit&#xe9; de Versailles-Saint-Quentin-en-Yvelines, UMS 011, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robineau</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Lille, Centre Hospitalier de Tourcoing, ULR 2694-METRICS: &#xc9;valuation des technologies de sant&#xe9; et des pratiques m&#xe9;dicales, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, INSERM, Institut Pierre Louis d'Epid&#xe9;miologie et de Sant&#xe9; Publique, D&#xe9;partement de Sant&#xe9; Publique, H&#xf4;pital Saint-Antoine, Assistance publique-H&#xf4;pitaux de Paris (AP-HP), Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carrat</LastName><ForeName>Fabrice</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, INSERM, Institut Pierre Louis d'Epid&#xe9;miologie et de Sant&#xe9; Publique, D&#xe9;partement de Sant&#xe9; Publique, H&#xf4;pital Saint-Antoine, Assistance publique-H&#xf4;pitaux de Paris (AP-HP), Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Touvier</LastName><ForeName>Mathilde</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sorbonne Paris Nord University, INSERM U1153, Inrae U1125, Cnam, Nutritional Epidemiology Research Team (EREN), Epidemiology and Statistics Research Center-University of Paris (CRESS), Bobigny, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Severi</LastName><ForeName>Gianluca</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Paris-Saclay, UVSQ, INSERM, CESP U1018, Gustave Roussy, Villejuif, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Statistics, Computer Science, Applications "G. Parenti," University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Lamballerie</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Unit&#xe9; des Virus Emergents, UVE: Aix Marseille Universit&#xe9;, IRD 190, INSERM 1207, Institut Hospitalo-Universitaire M&#xe9;diterran&#xe9;e Infection, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blanch&#xe9;</LastName><ForeName>H&#xe9;l&#xe8;ne</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Centre d'Etude du Polymorphisme Humain, Fondation Jean Dausset, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deleuze</LastName><ForeName>Jean-Fran&#xe7;ois</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Centre d'Etude du Polymorphisme Humain, Fondation Jean Dausset, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gouraud</LastName><ForeName>Cl&#xe9;ment</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>AP-HP, H&#xf4;pital H&#xf4;tel-Dieu, D&#xe9;partement M&#xe9;dico-Universitaire Psychiatrie et Addictologie, Service de Psychiatrie de l'adulte, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoertel</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Paris, AP-HP, H&#xf4;pital Corentin-Celton, DMU Psychiatrie et Addictologie, Service de Psychiatrie de l'adulte et du sujet &#xe2;g&#xe9;, INSERM, Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR_S1266, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ranque</LastName><ForeName>Brigitte</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Paris, AP-HP, H&#xf4;pital Europ&#xe9;en Georges-Pompidou, DMU endocrinologie, ophtalmologie, m&#xe9;decine infectieuse, m&#xe9;decine interne &amp; immunologie, m&#xe9;decine sociale, Service de M&#xe9;decine interne, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldberg</LastName><ForeName>Marcel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Paris, "Population-based Cohorts Unit," Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale (INSERM), Paris Saclay University, Universit&#xe9; de Versailles-Saint-Quentin-en-Yvelines, UMS 011, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zins</LastName><ForeName>Marie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Paris, "Population-based Cohorts Unit," Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale (INSERM), Paris Saclay University, Universit&#xe9; de Versailles-Saint-Quentin-en-Yvelines, UMS 011, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemogne</LastName><ForeName>C&#xe9;dric</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Paris, AP-HP, H&#xf4;pital H&#xf4;tel-Dieu, DMU Psychiatrie et Addictologie, Service de Psychiatrie de l'adulte, INSERM, IPNP, UMR_S1266, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Sant&#xe9;, Pratiques, Relations et In&#xe9;galit&#xe9;s Sociales en Population G&#xe9;n&#xe9;rale Pendant la Crise COVID-19&#x2013;S&#xe9;rologie (SAPRIS-SERO) Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Intern Med</MedlineTA><NlmUniqueID>101589534</NlmUniqueID><ISSNLinking>2168-6106</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>JAMA Intern Med. 2022 May 01;182(5):1. doi: 10.1001/jamainternmed.2022.0451</RefSource><PMID Version="1">35311908</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>JAMA Intern Med. 2022 May 1;182(5):579. doi: 10.1001/jamainternmed.2022.0450</RefSource><PMID Version="1">35311910</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Intern Med. 2022 May 1;182(5):576-577. doi: 10.1001/jamainternmed.2022.0418</RefSource><PMID Version="1">35311913</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Intern Med. 2022 May 1;182(5):577-578. doi: 10.1001/jamainternmed.2022.0424</RefSource><PMID Version="1">35311915</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Intern Med. 2022 May 1;182(5):577. doi: 10.1001/jamainternmed.2022.0421</RefSource><PMID Version="1">35311925</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000087124" MajorTopicYN="N">COVID-19 Serological Testing</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057566" MajorTopicYN="Y">Self Report</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="Y">Syndrome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Robineau reported personal fees and nonfinancial support from Gilead, ViiV Healthcare, and Merck Sharp &amp; Dohme Corp outside the submitted work. Dr Carrat reported personal fees from Sanofi outside the submitted work. Dr de Lamballerie reported grants from the French Ministry of Research and the French Institute of Health and Medical Research during the conduct of the study. Dr Hoertel reported personal fees and nonfinancial support from Lundbeck outside the submitted work. Dr Lemogne reported personal fees from Boehringer Ingelheim, Janssen-Cilag, Lundbeck, and Otsuka Pharmaceutical outside the submitted work. No other disclosures were reported.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Kab</LastName><ForeName>Sofiane</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Renuy</LastName><ForeName>Adeline</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Le-Got</LastName><ForeName>Stephane</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ribet</LastName><ForeName>Celine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wiernik</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldberg</LastName><ForeName>Marcel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zins</LastName><ForeName>Marie</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Artaud</LastName><ForeName>Fanny</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gerbouin-R&#xe9;rolle</LastName><ForeName>Pascale</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Enguix</LastName><ForeName>M&#xe9;lody</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laplanche</LastName><ForeName>Camille</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gomes-Rima</LastName><ForeName>Roselyn</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoang</LastName><ForeName>Lyan</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Correia</LastName><ForeName>Emmanuelle</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barry</LastName><ForeName>Alpha Amadou</ForeName><Initials>AA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Senina</LastName><ForeName>Nad&#xe8;ge</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Severi</LastName><ForeName>Gianluca</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Allegre</LastName><ForeName>Julien</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Szabo de Edelenyi</LastName><ForeName>Fabien</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Druesne-Pecollo</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Esseddik</LastName><ForeName>Younes</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hercberg</LastName><ForeName>Serge</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Touvier</LastName><ForeName>Mathilde</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Charles</LastName><ForeName>Marie-Aline</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ancel</LastName><ForeName>Pierre-Yves</ForeName><Initials>PY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benhammou</LastName><ForeName>Val&#xe9;rie</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ritmi</LastName><ForeName>Anass</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marchand</LastName><ForeName>Laetitia</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zaros</LastName><ForeName>C&#xe9;cile</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lordmi</LastName><ForeName>Elodie</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Candea</LastName><ForeName>Adriana</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Visme</LastName><ForeName>Sophie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simeon</LastName><ForeName>Thierry</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thierry</LastName><ForeName>Xavier</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Geay</LastName><ForeName>Bertrand</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dufourg</LastName><ForeName>Marie-Noelle</ForeName><Initials>MN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Milcent</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rahib</LastName><ForeName>Delphine</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lydie</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lusivika-Nzinga</LastName><ForeName>Clovis</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pannetier</LastName><ForeName>Gregory</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lapidus</LastName><ForeName>Nathanael</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goderel</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dorival</LastName><ForeName>C&#xe9;line</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nicol</LastName><ForeName>J&#xe9;r&#xf4;me</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carrat</LastName><ForeName>Fabrice</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lai</LastName><ForeName>Cindy</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belhadji</LastName><ForeName>Liza</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Esperou</LastName><ForeName>H&#xe9;l&#xe8;ne</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Couffin-Cadiergues</LastName><ForeName>Sandrine</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gagliolo</LastName><ForeName>Jean-Marie</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blanch&#xe9;</LastName><ForeName>H&#xe9;l&#xe8;ne</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>S&#xe9;baoun</LastName><ForeName>Jean-Marc</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beaudoin</LastName><ForeName>Jean-Christophe</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gressin</LastName><ForeName>Laetitia</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morel</LastName><ForeName>Val&#xe9;rie</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ouili</LastName><ForeName>Ouissam</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deleuze</LastName><ForeName>Jean-Fran&#xe7;ois</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ninove</LastName><ForeName>Laetitia</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Priet</LastName><ForeName>St&#xe9;phane</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saba Villarroel</LastName><ForeName>Paola Mariela</ForeName><Initials>PM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fouri&#xe9;</LastName><ForeName>Toscane</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mohamed Ali</LastName><ForeName>Souand</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Amroun</LastName><ForeName>Abdenour</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seston</LastName><ForeName>Morgan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ayhan</LastName><ForeName>Nazli</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pastorino</LastName><ForeName>Boris</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Lamballerie</LastName><ForeName>Xavier</ForeName><Initials>X</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>8</Day><Hour>12</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>11</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34747982</ArticleId><ArticleId IdType="pmc">PMC8576624</ArticleId><ArticleId IdType="doi">10.1001/jamainternmed.2021.6454</ArticleId><ArticleId IdType="pii">2785832</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nehme M, Braillard O, Alcoba G, et al. ; COVICARE TEAM . COVID-19 symptoms: longitudinal evolution and persistence in outpatient settings. Ann Intern Med. 2021;174(5):723-725. doi:10.7326/M20-5926</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-5926</ArticleId><ArticleId IdType="pmc">PMC7741180</ArticleId><ArticleId IdType="pubmed">33284676</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594(7862):259-264. doi:10.1038/s41586-021-03553-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03553-9</ArticleId><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H, Raza S, Nowell J, Young M, Edison P. Long covid&#x2014;mechanisms, risk factors, and management. BMJ. 2021;374:n1648. doi:10.1136/bmj.n1648</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahase E. Covid-19: what do we know about &#x201c;long covid&#x201d;? BMJ. 2020;370:m2815. doi:10.1136/bmj.m2815</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m2815</ArticleId><ArticleId IdType="pubmed">32665317</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al. . Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601-615. doi:10.1038/s41591-021-01283-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Yelin D, Wirtheim E, Vetter P, et al. . Long-term consequences of COVID-19: research needs. Lancet Infect Dis. 2020;20(10):1115-1117. doi:10.1016/S1473-3099(20)30701-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30701-5</ArticleId><ArticleId IdType="pmc">PMC7462626</ArticleId><ArticleId IdType="pubmed">32888409</ArticleId></ArticleIdList></Reference><Reference><Citation>CONSTANCES. 220 000 Volontaires pour am&#xe9;liorer la sant&#xe9; de demain [in French]. 2021. Accessed October 6, 2021. https://www.constances.fr/</Citation></Reference><Reference><Citation>Zins M, Goldberg M; CONSTANCES team . The French CONSTANCES population-based cohort: design, inclusion and follow-up. Eur J Epidemiol. 2015;30(12):1317-1328. doi:10.1007/s10654-015-0096-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-015-0096-4</ArticleId><ArticleId IdType="pmc">PMC4690834</ArticleId><ArticleId IdType="pubmed">26520638</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrat F, Touvier M, Severi G, et al. ; SAPRIS study group . Incidence and risk factors of COVID-19-like symptoms in the French general population during the lockdown period: a multi-cohort study. BMC Infect Dis. 2021;21(1):169. doi:10.1186/s12879-021-05864-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-021-05864-8</ArticleId><ArticleId IdType="pmc">PMC7875161</ArticleId><ArticleId IdType="pubmed">33568097</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrat F, de Lamballerie X, Rahib D, et al. ; SAPRIS and SAPRIS-SERO study groups . Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multicohort study. Int J Epidemiol.Published online July 19, 2021. doi:10.1093/ije/dyab110</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyab110</ArticleId><ArticleId IdType="pmc">PMC8344948</ArticleId><ArticleId IdType="pubmed">34293141</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel EU, Bloch EM, Clarke W, et al. . Comparative performance of five commercially available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals with high neutralizing titers. J Clin Microbiol. 2021;59(2):e02257-e20. doi:10.1128/JCM.02257-20</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.02257-20</ArticleId><ArticleId IdType="pmc">PMC8111143</ArticleId><ArticleId IdType="pubmed">33139419</ArticleId></ArticleIdList></Reference><Reference><Citation>Morin AJ, Moullec G, Ma&#xef;ano C, Layet L, Just JL, Ninot G. Psychometric properties of the Center for Epidemiologic Studies Depression Scale (CES-D) in French clinical and nonclinical adults. Rev Epidemiol Sante Publique. 2011;59(5):327-340. doi:10.1016/j.respe.2011.03.061</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.respe.2011.03.061</ArticleId><ArticleId IdType="pubmed">21925817</ArticleId></ArticleIdList></Reference><Reference><Citation>Havervall S, Rosell A, Phillipson M, et al. . Symptoms and functional impairment assessed 8 months after mild COVID-19 among health care workers. JAMA. 2021;325(19):2015-2016. doi:10.1001/jama.2021.5612</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.5612</ArticleId><ArticleId IdType="pmc">PMC8027932</ArticleId><ArticleId IdType="pubmed">33825846</ArticleId></ArticleIdList></Reference><Reference><Citation>Amin-Chowdhury Z, Ladhani SN. Causation or confounding: why controls are critical for characterizing long COVID. Nat Med. 2021;27(7):1129-1130. doi:10.1038/s41591-021-01402-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01402-w</ArticleId><ArticleId IdType="pubmed">34140704</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherlinger M, Felten R, Gallais F, et al. . Refining &#x201c;Long-COVID&#x201d; by a prospective multimodal evaluation of patients with long-term symptoms attributed to SARS-CoV-2 infection. Infect Dis Ther. 2021;10(3):1747-1763. doi:10.1007/s40121-021-00484-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40121-021-00484-w</ArticleId><ArticleId IdType="pmc">PMC8270770</ArticleId><ArticleId IdType="pubmed">34245450</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, et al. . Attributes and predictors of long COVID. Nat Med. 2021;27(4):626-631. doi:10.1038/s41591-021-01292-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Abell&#xe1;n J, Padilla S, Fern&#xe1;ndez-Gonz&#xe1;lez M, et al. . Antibody response to SARS-CoV-2 is associated with long-term clinical outcome in patients with COVID-19: a longitudinal study. J Clin Immunol. 2021;41(7):1490-1501. doi:10.1007/s10875-021-01083-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-021-01083-7</ArticleId><ArticleId IdType="pmc">PMC8285689</ArticleId><ArticleId IdType="pubmed">34273064</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta SD, Talwar A, Lee JT. A proposed framework and timeline of the spectrum of disease due to SARS-CoV-2 infection: illness beyond acute infection and public health implications. JAMA. 2020;324(22):2251-2252. doi:10.1001/jama.2020.22717</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.22717</ArticleId><ArticleId IdType="pubmed">33206133</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiech K. Deconstructing the sensation of pain: the influence of cognitive processes on pain perception. Science. 2016;354(6312):584-587. doi:10.1126/science.aaf8934</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf8934</ArticleId><ArticleId IdType="pubmed">27811269</ArticleId></ArticleIdList></Reference><Reference><Citation>Henningsen P, G&#xfc;ndel H, Kop WJ, et al. ; EURONET-SOMA Group . Persistent physical symptoms as perceptual dysregulation: a neuropsychobehavioral model and its clinical implications. Psychosom Med. 2018;80(5):422-431. doi:10.1097/PSY.0000000000000588</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PSY.0000000000000588</ArticleId><ArticleId IdType="pubmed">29621046</ArticleId></ArticleIdList></Reference><Reference><Citation>Klem F, Wadhwa A, Prokop LJ, et al. . Prevalence, risk factors, and outcomes of irritable bowel syndrome after infectious enteritis: a systematic review and meta-analysis. Gastroenterology. 2017;152(5):1042-1054. doi:10.1053/j.gastro.2016.12.039</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.12.039</ArticleId><ArticleId IdType="pmc">PMC5367939</ArticleId><ArticleId IdType="pubmed">28069350</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran VT, Riveros C, Clepier B, et al. . Development and validation of the long covid symptom and impact tools, a set of patient-reported instruments constructed from patients&#x2019; lived experience. Clin Infect Dis. Published online April 29, 2021. doi:10.1093/cid/ciab352</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab352</ArticleId><ArticleId IdType="pmc">PMC8135558</ArticleId><ArticleId IdType="pubmed">33912905</ArticleId></ArticleIdList></Reference><Reference><Citation>Henningsen P, Zipfel S, Sattel H, Creed F. Management of functional somatic syndromes and bodily distress. Psychother Psychosom. 2018;87(1):12-31. doi:10.1159/000484413</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000484413</ArticleId><ArticleId IdType="pubmed">29306954</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>